News

PipelineReview.com7m

Pfizer Provides Update on Phase 3 Inclacumab Study for the Treatment of People with Sickle Cell Disease

NEW YORK, NY, USA I August 15, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an ...
PipelineReview.com59m

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer

SÖDERTÄLJE, Sweden I August 18, 2025 I Anocca AB (‘Anocca’ or the ‘Company’), a leading clinical-stage T-cell immunotherapy company, has successfully raised ...
PipelineReview.com1h

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA ...

ROCKVILLE, MD, USA and SUZHOU, China I August 17, 2025 I Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...
PipelineReview.com11h

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

CHATHAM, NJ, USA I August 15, 2025 I Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...
PipelineReview.com1d

Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis

PLAINSBORO, NJ, USA I August 15, 2025 I Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...
PipelineReview.com1d

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory ...

GERMANTOWN, MD, USA I August 15, 2025 I Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision ...
PipelineReview.com1d

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential ...
PipelineReview.com1d

Novel Gene Therapy for ALS cleared for global trials in China and the U.S.

BEIJING, China I August 15, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies ...
PipelineReview.com5d

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Co…

SAN DIEGO, CA, USA I August 12, 2025 I Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage ...
PipelineReview.com3d

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

Superluminal is headquartered in Lilly Gateway Labs, Boston, and is backed by a strong network of investors, including RA Capital Management, Insight Partners, NVentures (NVIDIA’s venture capital arm) ...
PipelineReview.com3d

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung ...

TOKYO, Japan & BASKING RIDGE, NJ, USA I August 14, 2025 I Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug ...
PipelineReview.com6d

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

BASEL, Switzerland I August 12, 2025 I Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus ...